vaclav-volrab-shutterstock-com-leap-

Vaclav Volrab / Shutterstock.com

6 December 2016AmericasKaren Mangasarian and Ryan Murphey

Life sciences transactions: look before you leap

Whether it is to replenish innovator pharmaceutical companies’ diminishing new product pipelines or because of the allure of new platform technologies, the life sciences industry has been an active sector for transactions of various kinds.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

UKIPO rejects Boehringer’s SPC for horse inhaler

Bayer, Orion take on Indian generic over $117bn drug

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?